Form 4: RAPT Director Lori Lyons-Williams Receives RSU Grant

RAPT Therapeutics director Lori Lyons-Williams was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.

Summary

• Lori Lyons-Williams, a Director of RAPT Therapeutics, Inc., acquired 4,956 shares of common stock.
• This acquisition occurred on January 30, 2026, and was a grant of restricted stock units (RSUs).
• The RSUs were granted at a price of $0 and represent a contingent right to receive one share of common stock upon vesting.
• The RSUs will fully vest on the first anniversary of the grant date, as per the Issuer's Amended & Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine corporate governance event, reflecting standard director compensation practices. It's neither significantly positive nor negative for the company's immediate operational or financial outlook, but it does align director incentives with shareholder value.

Positives

• The grant of RSUs aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a standard compensation practice for non-employee directors, indicating adherence to established corporate governance policies.

Risks

• The value of the RSU grant is subject to the future performance of RAPT Therapeutics' common stock, meaning the actual realized value could be lower than the value at the grant date if the stock price declines.
• The RSUs are subject to a vesting period, meaning the director must remain with the company for one year from the grant date to fully realize the shares.

Future Outlook

The RSUs are scheduled to fully vest on the first anniversary of the grant date, indicating a future milestone for the director's compensation.

Management Comments

• Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units, is a common practice in the biotechnology and pharmaceutical industries for non-employee directors. This approach aligns director incentives with long-term shareholder value creation, a standard across many publicly traded companies, particularly those in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The grant of RSUs to a non-employee director is a standard practice in publicly traded companies, particularly in the biotech sector, for attracting and retaining qualified board members.
• The vesting schedule, typically over one year, is also common for annual director equity grants, similar to practices seen at companies like Amgen (AMGN) or Gilead Sciences (GILD) for their non-executive directors.
• The $0 grant price is typical for RSU awards, as they represent a right to receive shares upon vesting, rather than an option to purchase.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Director Lori Lyons-Williams is a related party transaction, but it is a standard component of the company's non-employee director compensation policy.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholders, as the value of the compensation is tied to stock performance. It represents a dilution of existing shares upon vesting, but this is typically factored into compensation plans.
• Directors: Provides equity-based compensation, incentivizing long-term commitment and performance.

Next Steps

• The RSUs are scheduled to fully vest on January 30, 2027 (one year from the grant date).

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a non-employee director, which is a standard compensation practice. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific filing.

Keywords

RAPT Therapeutics, RAPT, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Lori Lyons-Williams